EMMPRIN (CD147)

Roman Nawroth(TUM Klinikum), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie), Amely Hartmann(Institut für Psychogerontologie), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), J. E. Gschwend(TUM Klinikum)

Der Urologe

August 7, 2008

10.1007/s00120-008-1828-9

Cited by 5

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

|The Lancet Oncology|2017|1.8k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

|Cancer Cell|2016|660